{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,9]],"date-time":"2026-04-09T20:31:24Z","timestamp":1775766684695,"version":"3.50.1"},"reference-count":83,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2013,5,1]],"date-time":"2013-05-01T00:00:00Z","timestamp":1367366400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Immunology and Allergy Clinics of North America"],"published-print":{"date-parts":[[2013,5]]},"DOI":"10.1016\/j.iac.2012.12.002","type":"journal-article","created":{"date-parts":[[2013,2,1]],"date-time":"2013-02-01T12:21:29Z","timestamp":1359721289000},"page":"237-249","source":"Crossref","is-referenced-by-count":23,"title":["NSAID Single-Drug\u2013Induced Reactions"],"prefix":"10.1016","volume":"33","author":[{"given":"Katharine M.","family":"Woessner","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mariana","family":"Castells","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.iac.2012.12.002_bib1","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1097\/01.all.0000173785.81024.33","article-title":"Epidemiology of hypersensitivity drug reactions","volume":"5","author":"Gomes","year":"2005","journal-title":"Curr Opin Allergy Clin Immunol"},{"key":"10.1016\/j.iac.2012.12.002_bib2","doi-asserted-by":"crossref","first-page":"233","DOI":"10.2174\/1568008013341235","article-title":"Update on sensitivity to nonsteroidal antiinflammatory drugs","volume":"1","author":"Nettis","year":"2001","journal-title":"Curr Drug Targets Immune Endocr Metabol Disord"},{"key":"10.1016\/j.iac.2012.12.002_bib3","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1111\/j.1398-9995.1980.tb01730.x","article-title":"Aspirin intolerance and recurrent urticaria in normal adults and children. Epidemiology and review","volume":"35","author":"Settipane","year":"1980","journal-title":"Allergy"},{"key":"10.1016\/j.iac.2012.12.002_bib4","doi-asserted-by":"crossref","first-page":"S126","DOI":"10.1016\/j.jaci.2009.10.028","article-title":"Drug allergy","volume":"125","author":"Khan","year":"2010","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.iac.2012.12.002_bib5","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1345\/aph.1A140","article-title":"Different risks for NSAID-induced anaphylaxis","volume":"36","author":"van Puijenbroek","year":"2002","journal-title":"Ann Pharmacother"},{"key":"10.1016\/j.iac.2012.12.002_bib6","first-page":"182","article-title":"Challenge-based clinical patterns of 223 Spanish patients with nonsteroidal anti-inflammatory-drug-induced-reactions","volume":"17","author":"Quiralte","year":"2007","journal-title":"J\u00a0Investig Allergol Clin Immunol"},{"key":"10.1016\/j.iac.2012.12.002_bib7","doi-asserted-by":"crossref","first-page":"1355","DOI":"10.1046\/j.1365-2222.1996.d01-300.x","article-title":"Drug-associated anaphylaxis: 20\u00a0years of reporting in The Netherlands (1974-1994) and review of the literature","volume":"26","author":"Van der Klauw","year":"1996","journal-title":"Clin Exp Allergy"},{"issue":"Suppl 4","key":"10.1016\/j.iac.2012.12.002_bib8","doi-asserted-by":"crossref","first-page":"148","DOI":"10.2165\/00003495-198600324-00011","article-title":"Analgesics, allergy and asthma","volume":"32","author":"Szczeklik","year":"1986","journal-title":"Drugs"},{"key":"10.1016\/j.iac.2012.12.002_bib9","doi-asserted-by":"crossref","first-page":"1217","DOI":"10.1111\/j.1365-2222.2009.03237.x","article-title":"Immunoglobulin E-mediated immediate allergic reactions to dipyrone: value of basophil activation test in the identification of patients","volume":"39","author":"Gomez","year":"2009","journal-title":"Clin Exp Allergy"},{"key":"10.1016\/j.iac.2012.12.002_bib10","doi-asserted-by":"crossref","first-page":"687","DOI":"10.2165\/00002018-200629080-00005","article-title":"Serious skin reactions and selective COX-2 inhibitors: a case series from prescription-event monitoring in England","volume":"29","author":"Layton","year":"2006","journal-title":"Drug Saf"},{"key":"10.1016\/j.iac.2012.12.002_bib11","first-page":"2234","article-title":"The risk of Stevens-Johnson syndrome and toxic epidermal necrolysis associated with nonsteroidal antiinflammatory drugs: a multinational perspective","volume":"30","author":"Mockenhaupt","year":"2003","journal-title":"J\u00a0Rheumatol"},{"key":"10.1016\/j.iac.2012.12.002_bib12","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1007\/s00277-002-0575-z","article-title":"Mastocytosis: current concepts in diagnosis and treatment","volume":"81","author":"Escribano","year":"2002","journal-title":"Ann Hematol"},{"key":"10.1016\/j.iac.2012.12.002_bib13","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1016\/j.iac.2004.03.001","article-title":"Aspirin and NSAID sensitivity","volume":"24","author":"Stevenson","year":"2004","journal-title":"Immunol Allergy Clin North Am"},{"key":"10.1016\/j.iac.2012.12.002_bib14","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1111\/j.1398-9995.1981.tb01842.x","article-title":"Idiosyncrasy to pyrazolone drugs","volume":"36","author":"Czerniawska-Mysik","year":"1981","journal-title":"Allergy"},{"key":"10.1016\/j.iac.2012.12.002_bib15","first-page":"295","article-title":"Angioedema and IgE antibodies to aspirin: a case report","volume":"62","author":"Blanca","year":"1989","journal-title":"Ann Allergy"},{"key":"10.1016\/j.iac.2012.12.002_bib16","doi-asserted-by":"crossref","first-page":"1622","DOI":"10.1056\/NEJM198706253162603","article-title":"Tryptase levels as an indicator of mast-cell activation in systemic anaphylaxis and mastocytosis","volume":"316","author":"Schwartz","year":"1987","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.iac.2012.12.002_bib17","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1111\/j.1365-2222.2005.2228.x","article-title":"Oral aspirin challenges in patients with a history of intolerance to single non-steroidal anti-inflammatory drugs","volume":"35","author":"Asero","year":"2005","journal-title":"Clin Exp Allergy"},{"key":"10.1016\/j.iac.2012.12.002_bib18","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1016\/j.mcna.2010.03.005","article-title":"NSAID hypersensitivity (respiratory, cutaneous, and generalized anaphylactic symptoms)","volume":"94","author":"Sanchez-Borges","year":"2010","journal-title":"Med Clin North Am"},{"key":"10.1016\/j.iac.2012.12.002_bib19","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1016\/S1081-1206(10)62580-X","article-title":"Paracetamol (acetaminophen) hypersensitivity","volume":"85","author":"de Paramo","year":"2000","journal-title":"Ann Allergy Asthma Immunol"},{"key":"10.1016\/j.iac.2012.12.002_bib20","first-page":"147","article-title":"Study of an anaphylactoid reaction to acetaminophen","volume":"43","author":"Liao","year":"2002","journal-title":"Acta Paediatr Taiwan"},{"key":"10.1016\/j.iac.2012.12.002_bib21","doi-asserted-by":"crossref","first-page":"e13707","DOI":"10.1371\/journal.pone.0013707","article-title":"Diclofenac hypersensitivity: antibody responses to the parent drug and relevant metabolites","volume":"5","author":"Harrer","year":"2010","journal-title":"PLoS One"},{"key":"10.1016\/j.iac.2012.12.002_bib22","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1111\/j.1365-2222.2010.03648.x","article-title":"Assessing potential determinants of positive provocation tests in subjects with NSAID hypersensitivity","volume":"41","author":"Viola","year":"2011","journal-title":"Clin Exp Allergy"},{"key":"10.1016\/j.iac.2012.12.002_bib23","doi-asserted-by":"crossref","first-page":"1749","DOI":"10.1001\/archinte.1995.00430160077008","article-title":"Anaphylaxis. A review of 266 cases","volume":"155","author":"Kemp","year":"1995","journal-title":"Arch Intern Med"},{"key":"10.1016\/j.iac.2012.12.002_bib24","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1111\/j.1398-9995.1974.tb01668.x","article-title":"IgE mediated and non-IgE mediated allergic-type reactions to aspirin","volume":"29","author":"Phills","year":"1974","journal-title":"Acta Allergol"},{"key":"10.1016\/j.iac.2012.12.002_bib25","first-page":"357","article-title":"Cutaneous drug reactions","volume":"53","author":"Svensson","year":"2001","journal-title":"Pharmacol Rev"},{"key":"10.1016\/j.iac.2012.12.002_bib26","doi-asserted-by":"crossref","first-page":"1272","DOI":"10.1056\/NEJM199411103311906","article-title":"Severe adverse cutaneous reactions to drugs","volume":"331","author":"Roujeau","year":"1994","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.iac.2012.12.002_bib27","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1046\/j.1365-2133.2001.04422.x","article-title":"Current causes of fixed drug eruption in the UK","volume":"145","author":"Savin","year":"2001","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.iac.2012.12.002_bib28","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1046\/j.1365-4362.1998.00451.x","article-title":"Drugs causing fixed eruptions: a study of 450 cases","volume":"37","author":"Mahboob","year":"1998","journal-title":"Int J Dermatol"},{"key":"10.1016\/j.iac.2012.12.002_bib29","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1111\/j.1365-4632.2004.01860.x","article-title":"Ibuprofen-induced acute generalized exanthematous pustulosis","volume":"43","author":"Yesudian","year":"2004","journal-title":"Int J Dermatol"},{"key":"10.1016\/j.iac.2012.12.002_bib30","doi-asserted-by":"crossref","first-page":"20","DOI":"10.5070\/D39JH591QQ","article-title":"Acute generalized exanthematous pustulosis induced by nimesulide","volume":"12","author":"Teixeira","year":"2006","journal-title":"Dermatol Online J"},{"key":"10.1016\/j.iac.2012.12.002_bib31","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1111\/j.1529-8019.2012.01474.x","article-title":"Acute generalized exanthematous pustulosis-like, folliculitic drug reaction pattern caused by celecoxib","volume":"24","author":"Pakdeethai","year":"2011","journal-title":"Dermatol Ther"},{"key":"10.1016\/j.iac.2012.12.002_bib32","doi-asserted-by":"crossref","first-page":"4","DOI":"10.5070\/D32J70833J","article-title":"Keratosis lichenoides chronica: report of a new case, with success of PUVA therapy","volume":"7","author":"Ghislain","year":"2001","journal-title":"Dermatol Online J"},{"key":"10.1016\/j.iac.2012.12.002_bib33","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1038\/sj.jid.5701033","article-title":"Stevens-Johnson syndrome and toxic epidermal necrolysis: assessment of medication risks with emphasis on recently marketed drugs. The EuroSCAR-study","volume":"128","author":"Mockenhaupt","year":"2008","journal-title":"J\u00a0Invest Dermatol"},{"key":"10.1016\/j.iac.2012.12.002_bib34","doi-asserted-by":"crossref","first-page":"203","DOI":"10.3904\/kjim.2012.27.2.203","article-title":"Causes and treatment outcomes of Stevens-Johnson syndrome and toxic epidermal necrolysis in 82 adult patients","volume":"27","author":"Kim","year":"2012","journal-title":"Korean J Intern Med"},{"key":"10.1016\/j.iac.2012.12.002_bib35","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1111\/j.1365-2125.2001.01323.x","article-title":"Acetylsalicylic acid and other salicylates in relation to Stevens-Johnson syndrome and toxic epidermal necrolysis","volume":"51","author":"Kaufman","year":"2001","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.iac.2012.12.002_bib36","first-page":"273","article-title":"Burn center care for patients with toxic epidermal necrolysis","volume":"180","author":"Kelemen","year":"1995","journal-title":"J\u00a0Am Coll Surg"},{"key":"10.1016\/j.iac.2012.12.002_bib37","doi-asserted-by":"crossref","first-page":"151","DOI":"10.2500\/108854195778666793","article-title":"The outcome of Stevens-Johnson syndrome treated with corticosteroids","volume":"16","author":"Cheriyan","year":"1995","journal-title":"Allergy Proc"},{"key":"10.1016\/j.iac.2012.12.002_bib38","doi-asserted-by":"crossref","first-page":"1475","DOI":"10.1056\/NEJM199511303332207","article-title":"Management of acquired bullous skin diseases","volume":"333","author":"Fine","year":"1995","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.iac.2012.12.002_bib39","doi-asserted-by":"crossref","first-page":"1417","DOI":"10.1016\/S0140-6736(97)11369-1","article-title":"Toxic epidermal necrolysis","volume":"351","author":"Becker","year":"1998","journal-title":"Lancet"},{"key":"10.1016\/j.iac.2012.12.002_bib40","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1126\/science.282.5388.490","article-title":"Inhibition of toxic epidermal necrolysis by blockade of CD95 with human intravenous immunoglobulin","volume":"282","author":"Viard","year":"1998","journal-title":"Science"},{"key":"10.1016\/j.iac.2012.12.002_bib41","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1001\/archderm.139.1.26","article-title":"Treatment of toxic epidermal necrolysis with high-dose intravenous immunoglobulins: multicenter retrospective analysis of 48 consecutive cases","volume":"139","author":"Prins","year":"2003","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.iac.2012.12.002_bib42","doi-asserted-by":"crossref","first-page":"1081","DOI":"10.1001\/archderm.139.8.1081-a","article-title":"Intravenous immunoglobulin for the treatment of toxic epidermal necrolysis","volume":"139","author":"Trent","year":"2003","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.iac.2012.12.002_bib43","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1001\/archderm.139.1.39","article-title":"Analysis of intravenous immunoglobulin for the treatment of toxic epidermal necrolysis using SCORTEN: the University of Miami experience","volume":"139","author":"Trent","year":"2003","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.iac.2012.12.002_bib44","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1001\/archderm.139.1.33","article-title":"Intravenous immunoglobulin treatment for Stevens-Johnson syndrome and toxic epidermal necrolysis: a prospective noncomparative study showing no benefit on mortality or progression","volume":"139","author":"Bachot","year":"2003","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.iac.2012.12.002_bib45","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1097\/01.BCR.0000124746.33279.86","article-title":"Intravenous immunoglobulin does not improve outcome in toxic epidermal necrolysis","volume":"25","author":"Shortt","year":"2004","journal-title":"J\u00a0Burn Care Rehabil"},{"key":"10.1016\/j.iac.2012.12.002_bib46","doi-asserted-by":"crossref","first-page":"710","DOI":"10.1111\/j.1365-2133.1996.tb06976.x","article-title":"Apoptosis as a mechanism of keratinocyte death in toxic epidermal necrolysis","volume":"134","author":"Paul","year":"1996","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.iac.2012.12.002_bib47","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1016\/j.jaci.2005.06.029","article-title":"Rapid resolution of toxic epidermal necrolysis with anti-TNF-alpha treatment","volume":"116","author":"Hunger","year":"2005","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.iac.2012.12.002_bib48","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1046\/j.1365-2133.2002.46833.x","article-title":"Antitumour necrosis factor-alpha antibodies (infliximab) in the treatment of a patient with toxic epidermal necrolysis","volume":"146","author":"Fischer","year":"2002","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.iac.2012.12.002_bib49","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1016\/S1085-5629(96)80038-1","article-title":"Drug-induced pseudolymphoma and drug hypersensitivity syndrome (Drug Rash with Eosinophilia and Systemic Symptoms: DRESS)","volume":"15","author":"Bocquet","year":"1996","journal-title":"Semin Cutan Med Surg"},{"key":"10.1016\/j.iac.2012.12.002_bib50","first-page":"556","article-title":"Clinical features of drug-induced hypersensitivity syndrome in 38 patients","volume":"20","author":"Um","year":"2010","journal-title":"J\u00a0Investig Allergol Clin Immunol"},{"key":"10.1016\/j.iac.2012.12.002_bib51","doi-asserted-by":"crossref","first-page":"521","DOI":"10.3346\/jkms.2008.23.3.521","article-title":"Drug Rash with Eosinophilia and Systemic Symptoms (DRESS) syndrome induced by celecoxib and anti-tuberculosis drugs","volume":"23","author":"Lee","year":"2008","journal-title":"J\u00a0Korean Med Sci"},{"key":"10.1016\/j.iac.2012.12.002_bib52","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1016\/j.jaad.2008.07.044","article-title":"Drug-induced hypersensitivity syndrome: drug reaction with eosinophilia and systemic symptoms (DRESS) syndrome induced by aspirin treatment of Kawasaki disease","volume":"60","author":"Kawakami","year":"2009","journal-title":"J\u00a0Am Acad Dermatol"},{"key":"10.1016\/j.iac.2012.12.002_bib53","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1016\/j.anai.2010.08.002","article-title":"Drug allergy: an updated practice parameter","volume":"105","author":"Joint Task Force on Practice Parameters","year":"2010","journal-title":"Ann Allergy Asthma Immunol"},{"key":"10.1016\/j.iac.2012.12.002_bib54","first-page":"510","article-title":"Case reports: treatment of nevirapine-associated dress syndrome with intravenous immune globulin (IVIG)","volume":"4","author":"Fields","year":"2005","journal-title":"J\u00a0Drugs Dermatol"},{"key":"10.1016\/j.iac.2012.12.002_bib55","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/S0272-5231(03)00141-2","article-title":"Drug-induced eosinophilic lung disease","volume":"25","author":"Allen","year":"2004","journal-title":"Clin Chest Med"},{"key":"10.1016\/j.iac.2012.12.002_bib56","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1093\/rheumatology\/25.1.5","article-title":"Pulmonary alveolitis and NSAIDs\u2014fact or fiction?","volume":"25","author":"Weber","year":"1986","journal-title":"Br J Rheumatol"},{"key":"10.1016\/j.iac.2012.12.002_bib57","doi-asserted-by":"crossref","first-page":"1521","DOI":"10.1001\/archinte.1992.00400190139026","article-title":"Nonsteroidal anti-inflammatory drug-associated pulmonary infiltrates with eosinophilia. Review of the literature and Food and Drug Administration Adverse Drug Reaction reports","volume":"152","author":"Goodwin","year":"1992","journal-title":"Arch Intern Med"},{"key":"10.1016\/j.iac.2012.12.002_bib58","doi-asserted-by":"crossref","first-page":"215","DOI":"10.2165\/00002018-200022030-00005","article-title":"Drug-induced aseptic meningitis: diagnosis and management","volume":"22","author":"Jolles","year":"2000","journal-title":"Drug Saf"},{"key":"10.1016\/j.iac.2012.12.002_bib59","doi-asserted-by":"crossref","first-page":"1185","DOI":"10.1001\/archinte.159.11.1185","article-title":"The challenge of drug-induced aseptic meningitis","volume":"159","author":"Moris","year":"1999","journal-title":"Arch Intern Med"},{"key":"10.1016\/j.iac.2012.12.002_bib60","first-page":"484","article-title":"Ibuprofen-induced aseptic meningoencephalitis confirmed by drug challenge","volume":"21","author":"Moreno-Ancillo","year":"2011","journal-title":"J\u00a0Investig Allergol Clin Immunol"},{"key":"10.1016\/j.iac.2012.12.002_bib61","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1136\/pmj.79.931.295","article-title":"Recurrent aseptic meningitis due to different non-steroidal anti-inflammatory drugs including rofecoxib","volume":"79","author":"Ashwath","year":"2003","journal-title":"Postgrad Med J"},{"key":"10.1016\/j.iac.2012.12.002_bib62","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1001\/archinte.1982.00340140167031","article-title":"Sulindac-induced aseptic meningitis","volume":"142","author":"Ballas","year":"1982","journal-title":"Arch Intern Med"},{"key":"10.1016\/j.iac.2012.12.002_bib63","doi-asserted-by":"crossref","first-page":"818","DOI":"10.1111\/j.1398-9995.2011.02557.x","article-title":"Hypersensitivity to nonsteroidal anti-inflammatory drugs (NSAIDs) - classification diagnosis and management: review of the EAACI\/ENDA(#) and GA2LEN\/HANNA*","volume":"66","author":"Kowalski","year":"2011","journal-title":"Allergy"},{"key":"10.1016\/j.iac.2012.12.002_bib64","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1111\/j.1600-0536.1993.tb04536.x","article-title":"Topical NSAID allergic contact dermatitis. Italian experience","volume":"29","author":"Pigatto","year":"1993","journal-title":"Contact Derm"},{"key":"10.1016\/j.iac.2012.12.002_bib65","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1016\/0190-9622(95)91271-1","article-title":"Cutaneous photosensitivity diseases induced by exogenous agents","volume":"33","author":"Gould","year":"1995","journal-title":"J\u00a0Am Acad Dermatol"},{"key":"10.1016\/j.iac.2012.12.002_bib66","doi-asserted-by":"crossref","first-page":"339","DOI":"10.2165\/00002018-200022050-00002","article-title":"Photosensitivity to ketoprofen: mechanisms and pharmacoepidemiological data","volume":"22","author":"Bagheri","year":"2000","journal-title":"Drug Saf"},{"key":"10.1016\/j.iac.2012.12.002_bib67","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1111\/j.1600-0536.2008.01367.x","article-title":"Drug-elicited systemic allergic (contact) dermatitis\u2014update and possible pathomechanisms","volume":"59","author":"Thyssen","year":"2008","journal-title":"Contact Derm"},{"key":"10.1016\/j.iac.2012.12.002_bib68","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1111\/j.1365-2222.2007.02742.x","article-title":"Delayed drug hypersensitivity reactions\u2014new concepts","volume":"37","author":"Posadas","year":"2007","journal-title":"Clin Exp Allergy"},{"key":"10.1016\/j.iac.2012.12.002_bib69","doi-asserted-by":"crossref","first-page":"536","DOI":"10.4103\/0378-6323.82424","article-title":"Systemic (allergic) contact dermatitis to diclofenac","volume":"77","author":"Lakshmi","year":"2011","journal-title":"Indian J Dermatol Venereol Leprol"},{"key":"10.1016\/j.iac.2012.12.002_bib70","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1111\/j.0105-1873.2005.0483d.x","article-title":"Valdecoxib-induced systemic contact dermatitis confirmed by positive patch test","volume":"52","author":"Jaeger","year":"2005","journal-title":"Contact Derm"},{"key":"10.1016\/j.iac.2012.12.002_bib71","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1016\/j.iac.2009.04.010","article-title":"Skin testing in delayed reactions to drugs","volume":"29","author":"Barbaud","year":"2009","journal-title":"Immunol Allergy Clin North Am"},{"key":"10.1016\/j.iac.2012.12.002_bib72","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1097\/ACI.0b013e32832cda4c","article-title":"Fixed drug eruption: pathogenesis and diagnostic tests","volume":"9","author":"Shiohara","year":"2009","journal-title":"Curr Opin Allergy Clin Immunol"},{"key":"10.1016\/j.iac.2012.12.002_bib73","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1111\/j.1600-0536.1996.tb02237.x","article-title":"Photopatch test reactivity: effect of photoallergen concentration and UVA dosaging","volume":"34","author":"Hasan","year":"1996","journal-title":"Contact Derm"},{"key":"10.1016\/j.iac.2012.12.002_bib74","doi-asserted-by":"crossref","first-page":"854","DOI":"10.1034\/j.1398-9995.2003.00279.x","article-title":"Drug provocation testing in the diagnosis of drug hypersensitivity reactions: general considerations","volume":"58","author":"Aberer","year":"2003","journal-title":"Allergy"},{"key":"10.1016\/j.iac.2012.12.002_bib75","doi-asserted-by":"crossref","first-page":"1520","DOI":"10.1056\/NEJM200011233432103","article-title":"Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. VIGOR Study Group","volume":"343","author":"Bombardier","year":"2000","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.iac.2012.12.002_bib76","doi-asserted-by":"crossref","first-page":"2021","DOI":"10.1016\/S0140-6736(04)17514-4","article-title":"Risk of cardiovascular events and rofecoxib: cumulative meta-analysis","volume":"364","author":"Juni","year":"2004","journal-title":"Lancet"},{"key":"10.1016\/j.iac.2012.12.002_bib77","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1016\/S0140-6736(05)17864-7","article-title":"Risk of acute myocardial infarction and sudden cardiac death in patients treated with cyclo-oxygenase 2 selective and non-selective non-steroidal anti-inflammatory drugs: nested case-control study","volume":"365","author":"Graham","year":"2005","journal-title":"Lancet"},{"key":"10.1016\/j.iac.2012.12.002_bib78","doi-asserted-by":"crossref","first-page":"1092","DOI":"10.1056\/NEJMoa050493","article-title":"Cardiovascular events associated with rofecoxib in a colorectal adenoma chemoprevention trial","volume":"352","author":"Bresalier","year":"2005","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.iac.2012.12.002_bib79","doi-asserted-by":"crossref","first-page":"1071","DOI":"10.1056\/NEJMoa050405","article-title":"Cardiovascular risk associated with celecoxib in a clinical trial for colorectal adenoma prevention","volume":"352","author":"Solomon","year":"2005","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.iac.2012.12.002_bib80","doi-asserted-by":"crossref","first-page":"1071","DOI":"10.1016\/S0140-6736(02)11131-7","article-title":"COX-2 selective non-steroidal anti-inflammatory drugs and risk of serious coronary heart disease","volume":"360","author":"Ray","year":"2002","journal-title":"Lancet"},{"key":"10.1016\/j.iac.2012.12.002_bib81","doi-asserted-by":"crossref","first-page":"2068","DOI":"10.1161\/01.CIR.0000127578.21885.3E","article-title":"Relationship between selective cyclooxygenase-2 inhibitors and acute myocardial infarction in older adults","volume":"109","author":"Solomon","year":"2004","journal-title":"Circulation"},{"key":"10.1016\/j.iac.2012.12.002_bib82","doi-asserted-by":"crossref","first-page":"1751","DOI":"10.1016\/S0140-6736(04)16299-5","article-title":"Cyclo-oxygenase-2 inhibitors versus non-selective non-steroidal anti-inflammatory drugs and congestive heart failure outcomes in elderly patients: a population-based cohort study","volume":"363","author":"Mamdani","year":"2004","journal-title":"Lancet"},{"key":"10.1016\/j.iac.2012.12.002_bib83","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1007\/1-4020-5688-5_8","article-title":"A\u00a0biological rationale for the cardiotoxic effects of rofecoxib: comparative analysis with other COX-2 selective agents and NSAids","volume":"42","author":"Mason","year":"2007","journal-title":"Subcell Biochem"}],"container-title":["Immunology and Allergy Clinics of North America"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0889856112001488?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0889856112001488?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2022,2,7]],"date-time":"2022-02-07T03:48:51Z","timestamp":1644205731000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0889856112001488"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,5]]},"references-count":83,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2013,5]]}},"alternative-id":["S0889856112001488"],"URL":"https:\/\/doi.org\/10.1016\/j.iac.2012.12.002","relation":{},"ISSN":["0889-8561"],"issn-type":[{"value":"0889-8561","type":"print"}],"subject":[],"published":{"date-parts":[[2013,5]]}}}